AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IONIS PHARMACEUTICALS INC Director's Dealing 2013

Mar 21, 2013

30591_dirs_2013-03-21_5222cb56-e591-4010-8f1b-a9940b6ad0f7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2013-03-20

Reporting Person: KLEIN JOSEPH III (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-03-20	Common Stock	M	2500	$16.32	Acquired	2500	Indirect
2013-03-20	Common Stock	S	2500	$18.00	Disposed	0	Indirect
2013-03-20	Common Stock	M	1250	$9.22	Acquired	1250	Indirect
2013-03-20	Common Stock	S	1250	$18.00	Disposed	0	Indirect
2013-03-20	Common Stock	M	174	$5.93	Acquired	174	Indirect
2013-03-20	Common Stock	S	174	$18.00	Disposed	0	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8000	Direct

Footnotes

F1: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/7/2012.